Press coverage about Rhythm Pharmaceuticals (NASDAQ:RYTM) has been trending somewhat positive this week, Accern reports. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Rhythm Pharmaceuticals earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.3252196765249 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:
- BidaskClub Upgrades Rhythm Pharmaceuticals (RYTM) to Hold (americanbankingnews.com)
- Rhythm Pharmaceuticals Inc (RYTM) Expected to Post Earnings of -$0.44 Per Share (americanbankingnews.com)
- Cardiac Monitoring & Cardiac Rhythm Management Devices Market Fuelling the Growth to 2025 (openpr.com)
- Rhythm Pharmaceuticals (RYTM) Now Covered by Analysts at Cowen (americanbankingnews.com)
- Diurnal Group expects admission of new shares amid product launch funding (hl.co.uk)
Shares of RYTM stock traded down $0.73 during trading hours on Friday, reaching $19.46. 87,759 shares of the company’s stock were exchanged, compared to its average volume of 110,922. The company has a market cap of $550.87 and a PE ratio of -6.88. Rhythm Pharmaceuticals has a fifty-two week low of $16.80 and a fifty-two week high of $33.81.
A number of equities analysts have recently issued reports on RYTM shares. BidaskClub downgraded Rhythm Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, December 29th. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price target on shares of Rhythm Pharmaceuticals in a research report on Monday, February 26th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $31.25.
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.